EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Frequency of cefiderocol heteroresistance among patients treated with cefiderocol for carbapenem-resistant Acinetobacter baumannii infections

Ryan K Shields iD, Ava J Dorazio, Giusy Tiseo iD, Kevin M Squires, Alessandro Leonildi, Cesira Giordano, Ellen G Kline, Simona Barnini, Alina Iovleva iD, Marissa P Griffith, Daria Van Tyne iD, Yohei Doi iD und 1 weitere

JAC-Antimicrobial Resistance · 03.09.2024 · 6 (5)

DOI: 10.1093/jacamr/dlae146 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAC-Antimicrobial Resistance, online erschienen am 09.09.2024. Verfasst von Ryan K Shields und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIH.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cefiderocol exhibits potent in vitro activity against carbapenem-resistant Acinetobacter baumannii (CRAb), but this activity has not consistently translated to improved outcomes among patients. Cefiderocol heteroresistance, or the presence of a resistant subpopulation, has been proposed as one possible explanation. The objective of this study was to explore associations between heteroresistance and outcomes of patients with CRAb infections.

Methods

Baseline CRAb isolates were collected from 27 consecutive patients in the USA and Italy. Cefiderocol susceptibility was tested by broth microdilutions in triplicate. Heteroresistance was defined by population analysis profiling in duplicate. Resistance mechanisms and strain relatedness were evaluated through comparative genomic analysis.

Results

Overall, 59% of infecting CRAb isolates were identified as cefiderocol-heteroresistant; rates were higher among isolates from Italy (79%) than the USA (38%). The median Charlson Comorbidity and SOFA scores were 4 and 5, respectively; 44% of patients had pneumonia, which was the most common infection type. Rates of 28-day clinical success and survival were 30% and 73%, respectively. By broth microdilution, cefiderocol MICs ≥1 mg/L were associated with higher failure rates than MICs ≤0.5 mg/L (81% versus 55%). Rates of clinical failure were numerically higher among patients infected by cefiderocol-heteroresistant compared with susceptible CRAb (81% versus 55%). Whole-genome sequencing identified a premature stop codon in the TonB-dependent receptor gene piuA in six isolates, all of which were heteroresistant.

Conclusions

This pilot study supports the hypothesis that cefiderocol treatment failure may be associated with higher MICs and/or the presence of heteroresistance. Further studies are needed to confirm these findings.

Autor:innen und Institutionen

  • Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
  • Center for Innovative Antimicrobial Therapy, University of Pittsburgh, Pittsburgh, PA, USA.
  • Antibiotic Management Program, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
  • Department of Clinical and Experimental Medicine, Azienda Osperdaliero Universitaria Pisana, University of Pisa, Pisa, Italy.
  • Microbiology Unit, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy.
  • Center for Evolutionary Biology and Medicine, University of Pittsburgh, Pittsburgh, PA, USA.

ORCID-Profile: Ryan K Shields, Giusy Tiseo, Alina Iovleva, Daria Van Tyne, Yohei Doi, Marco Falcone

Förderung

  • NIAID NIH HHS
  • NIH

Zitieren

APA

Shields, R. K., Dorazio, A. J., Tiseo, G., Squires, K. M., Leonildi, A., Giordano, C., Kline, E. G., Barnini, S., Iovleva, A., Griffith, M. P., Van Tyne, D., Doi, Y., & Falcone, M. (2024). Frequency of cefiderocol heteroresistance among patients treated with cefiderocol for carbapenem-resistant Acinetobacter baumannii infections. JAC-Antimicrobial Resistance, 6(5). https://doi.org/10.1093/jacamr/dlae146

Vancouver

Shields RK, Dorazio AJ, Tiseo G, Squires KM, Leonildi A, Giordano C, et al. Frequency of cefiderocol heteroresistance among patients treated with cefiderocol for carbapenem-resistant Acinetobacter baumannii infections. JAC-Antimicrobial Resistance. 2024;6(5). doi:10.1093/jacamr/dlae146

BibTeX
@article{Shields2024,
  author = {Shields, Ryan K and Dorazio, Ava J and Tiseo, Giusy and Squires, Kevin M and Leonildi, Alessandro and Giordano, Cesira and Kline, Ellen G and Barnini, Simona and Iovleva, Alina and Griffith, Marissa P and Van Tyne, Daria and Doi, Yohei and Falcone, Marco},
  title = {Frequency of cefiderocol heteroresistance among patients treated with cefiderocol for carbapenem-resistant Acinetobacter baumannii infections},
  journal = {JAC-Antimicrobial Resistance},
  year = {2024},
  volume = {6},
  number = {5},
  doi = {10.1093/jacamr/dlae146}
}
Kostenlos starten →